Akebia Therapeutics Inc.
AKBA
NSD
Sector: Healthcare
Industry: Biotechnology
0.41
USD
-0.01
(-2.57%)
Optionable: Yes Market Cap: 77 M 90-day average vol: 9,743,807
Previous close: 0.4167 Open: 0.4152 Bid: 0.414 Ask: 0.414
52 week range
0.30 3.35
Last updated: Thursday 18th August 2022
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started todaySearch for a stock
Are you?
Chart
Financials
AKBA Income Statement
Annual
| Dec-12 | Dec-13 | Dec-14 | Dec-15 | Dec-16 | Dec-17 | Dec-18 | Dec-19 | Dec-20 | Dec-21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 2 M | 181 M | 208 M | 335 M | 295 M | 214 M |
| Cost of sales | -2 M | -753000 | -317000 | -654000 | -790000 | -1 M | 7 M | 108 M | 262 M | 115 M |
| Gross operating profit | 0 | 0 | 0 | 0 | 2 M | 181 M | 200 M | 190 M | -601000 | 60 M |
| Selling Gen & administrative expense | 3 M | 7 M | 15 M | 18 M | 22 M | 27 M | 87 M | 157 M | 157 M | 178 M |
| Research & development expense | 6 M | 9 M | 23 M | 43 M | 116 M | 231 M | 291 M | 323 M | 218 M | 148 M |
| Operating income | -9 M | -16 M | -38 M | -62 M | -136 M | -77 M | -178 M | -286 M | -376 M | -265 M |
| floaterest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| floaterest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other income net | 2 M | 3 M | 700000 | 287000 | -188000 | 204000 | 81000 | -794000 | 2 M | 2 M |
| Pre-tax Income (EBT) | -8 M | -13 M | -37 M | -61 M | -136 M | -74 M | -172 M | -286 M | -383 M | -283 M |
| Income taxes | 0 | 0 | 0 | 0 | 0 | 0 | -28 M | -7 M | 0 | 0 |
| Net income from total operations | -8 M | -13 M | -37 M | -61 M | -136 M | -74 M | -144 M | -280 M | -383 M | -283 M |
| Minority floaterest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total net income | -8 M | -13 M | -37 M | -61 M | -136 M | -74 M | -144 M | -280 M | -383 M | -283 M |
| Preferred dividends | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net income available for common | -8 M | -13 M | -37 M | -61 M | -136 M | -74 M | -144 M | -280 M | -383 M | -283 M |
| Depreciation | 2 M | 753000 | 317000 | 654000 | 790000 | 1 M | 1 M | 38 M | 34 M | 38 M |
| Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income before depreciation (EBITDA) | -9 M | -16 M | -38 M | -61 M | -136 M | -76 M | -176 M | -248 M | -343 M | -227 M |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Basic EPS total | -1.14 | -1.31 | -8.04 | -2.29 | -3.6 | -1.69 | -2.47 | -2.36 | -2.77 | -1.7 |
| Diluted EPS total | -1.14 | -1.31 | -8.04 | -2.29 | -3.6 | -1.69 | -2.47 | -2.36 | -2.77 | -1.7 |
Top MarketXLS Rank stocks
Call: 1-877-778-8358
I am so happy you are here. My name is Ankur and I am the founder/CEO of MarketXLS. Over the past four years, I have helped more than 2500 customers to implement their own investment research strategies and monitoring systems in Excel.
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started today
Stand with Ukraine
As the situation in Ukraine escalates, many of us in MarketXLS are left with emotions too overwhelming to name. If you’d like to show your support, but aren’t sure how to, we want to help make it easier for you to act.
For any amount donated, we’ll extend your MarketXLS subscription for double of the donated amount. Please send proof of your payment to support@marketxls.com to avail the extention
From all of us at MarketXLS, thank you!